{
    "organizations": [],
    "uuid": "a93de490e8634d7198a317cee7ba6f418f8787bb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-announces-positive-top-line/brief-pfizer-announces-positive-top-line-results-for-potential-biosimilar-to-rituxan-mabthera-idUSFWN1PJ11B",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 24, 2018 / 1:48 PM / in 10 minutes BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera Reuters Staff \nJan 24 (Reuters) - Pfizer Inc: \n* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN®/MABTHERA® \n* PFIZER INC - PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN(®)/MABTHERA(®) \n* PFIZER INC - RESULTS FROM COMPARATIVE REFLECTIONS B3281006 STUDY DEMONSTRATE EQUIVALENCE IN PATIENTS WITH INDOLENT FOLLICULAR LYMPHOMA \n* PFIZER INC - REFLECTIONS B3281006, A COMPARATIVE SAFETY AND EFFICACY STUDY OF PF-05280586 VERSUS MABTHERA(®) (RITUXIMAB-EU), MET ITS PRIMARY ENDPOINT \n* PFIZER - TRIAL DEMONSTRATED EQUIVALENCE IN OVERALL RESPONSE RATE FOR FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Source text for Eikon: Further company coverage:",
    "published": "2018-01-24T15:46:00.000+02:00",
    "crawled": "2018-01-24T16:02:12.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "announces",
        "positive",
        "result",
        "potential",
        "biosimilar",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "announces",
        "positive",
        "result",
        "potential",
        "biosimilar",
        "pfizer",
        "inc",
        "pfizer",
        "announces",
        "positive",
        "result",
        "potential",
        "biosimilar",
        "rituxan",
        "pfizer",
        "inc",
        "result",
        "comparative",
        "reflection",
        "b3281006",
        "study",
        "demonstrate",
        "equivalence",
        "patient",
        "indolent",
        "follicular",
        "lymphoma",
        "pfizer",
        "inc",
        "reflection",
        "b3281006",
        "comparative",
        "safety",
        "efficacy",
        "study",
        "versus",
        "mabthera",
        "met",
        "primary",
        "endpoint",
        "pfizer",
        "trial",
        "demonstrated",
        "equivalence",
        "overall",
        "response",
        "rate",
        "treatment",
        "patient",
        "low",
        "tumor",
        "burden",
        "follicular",
        "lymphoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}